APVO · Aptevo Therapeutics Inc.

Summary

Aptevo Therapeutics Inc. announced new interim data from two trials showing mipletamig in combination with venetoclax and azacitidine achieved an 86% clinical benefit rate with no cytokine release syndrome in 28 evaluable newly diagnosed AML patients unfit for intensive chemotherapy. The data highlights strong remission rates and safety, supporting potential enhancement of standard-of-care therapy.

Key takeaways

• 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients
• 79% achieved CR or CRi, 61% achieved CR
• 100% of patients free of cytokine release syndrome (CRS)
• 55% of CR/CRi patients reached measurable residual disease-negative (MRD-negative)
• 35% of patients with remissions had TP53 mutation
• 4 patients proceeded to allogeneic stem cell transplant